Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1080/09537104.2021.1962519 http://scihub22266oqcxt.onion/10.1080/09537104.2021.1962519 34384321!8425443!34384321     free     free     free       Platelets 2022 ; 33 (2): 192-199 Nephropedia Template TP {{tp|p=34384321|t=2022. Alterations in platelets during SARS-CoV-2 infection |pdf=|usr=}}{{34384321}} gab.com Text Alterations in platelets during SARS-CoV-2 infection JO: Platelets http://www.kidney.de/pget.php?&tw=1&pmid=34384321 #FOAvip Coronavirus disease 2019 (COVID-19) is a pandemic syndrome caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. SARS-CoV-2 infection induces a process of inflammation and thrombosis supported by an altered platelet activation state. This platelet activation is peculiar being characterized by the formation of platelet-leukocytes rather than platelet-platelet aggregates and by an increased procoagulant potential supported by elevated levels of TF positive platelets and microvesicles.Therapeutic strategies targeting, beyond systemic inflammation (i.e. with tocilizumab, an anti interleukin-6 receptor), this state of platelet activation might therefore be beneficial. Among the antithrombotic drugs proposed as candidates to treat patients with SARS-CoV-2 infection, antiplatelet drugs, such as aspirin are showing promising results. Twit Text FOAVip Alterations in platelets during SARS-CoV-2 infection ????Platelets http://www.kidney.de/pget.php?&tw=1&pmid=34384321 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34384321 #FOAvip English Wikipedia <ref>{{Cite pmid|34384321}}</ref> Alterations in platelets during SARS-CoV-2 infection #MMPMID34384321 Brambilla M; Canzano P; Becchetti A; Tremoli E; Camera M Platelets 2022[Feb]; 33 (2): 192-199 PMID34384321show ga Coronavirus disease 2019 (COVID-19) is a pandemic syndrome caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. SARS-CoV-2 infection induces a process of inflammation and thrombosis supported by an altered platelet activation state. This platelet activation is peculiar being characterized by the formation of platelet-leukocytes rather than platelet-platelet aggregates and by an increased procoagulant potential supported by elevated levels of TF positive platelets and microvesicles.Therapeutic strategies targeting, beyond systemic inflammation (i.e. with tocilizumab, an anti interleukin-6 receptor), this state of platelet activation might therefore be beneficial. Among the antithrombotic drugs proposed as candidates to treat patients with SARS-CoV-2 infection, antiplatelet drugs, such as aspirin are showing promising results. |Blood Platelets/*metabolism[MESH] |COVID-19/*blood[MESH] |Humans[MESH]Alterations in platelets during SARS-CoV-2 infection (epmc).pdf DeepDyve Pubget Overpricing